BD HorizonTM BV421 Biosimilar Anti-Human CD20 Rituximab297

Description

Two-color flow cytometric analysis of Human CD20 Rituximab Biosimilar expression on Human peripheral blood lymphocytes. Human whole blood was stained with APC Mouse Anti-Human CD19 antibody Cat. No. 555415 and with either BD OptiBuild BV421 IgG1, kappa N297A Human Isotype Control Cat. No. 756231; Left Plot or BD Horizon BV421 Biosimilar Anti-Human CD20 Rituximab297 antibody Cat. No. 570361/570431; Right Plot . The erythrocytes were lysed with BD FACS Lysing Solution Cat. No. 349202 . The bivariate pseudocolor density plot showing the correlated expression of CD20 Rituximab Biosimilar or Ig Isotype control staining versus CD19 was derived from gated events with the forward and side light-scatter characteristics of intact lymphocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo Software. Multiparameter flow cytometric analysis of Human CD20 Rituximab Biosimilar expression on Human peripheral blood leukocytes. Human whole blood was stained with either BD OptiBuild BV421 IgG1, kappa N297A Human Isotype Control Cat. No. 756231; Left Plot or BD Horizon BV421 Biosimilar Anti-Human CD20 Rituximab297 antibody Cat. No. 570361/570431; Right Plot . The erythrocytes were lysed with BD FACS Lysing Solution Cat. No. 349202 . The bivariate pseudocolor density plot showing the correlated expression of CD20 Rituximab Biosimilar or Ig Isotype control staining versus side light-scatter SSC-A signals was derived from gated events with the forward and side light-scatter characteristics of intact leukocyte populations. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo Software. Two-color flow cytometric analysis of Human CD20 Rituximab Biosimilar expression on Human peripheral blood lymphocytes. Human whole blood was stained with APC Mouse Anti-Human CD19 antibody Cat. No. 555415 and with either BD OptiBuild BV421 IgG1, kappa N297A Human Isotype Control Cat. No. 756231; Left Plot or BD Horizon BV421 Biosimilar Anti-Human CD20 Rituximab297 antibody Cat. No. 570361/570431; Right Plot . The erythrocytes were lysed with BD FACS Lysing Solution Cat. No. 349202 . The bivariate pseudocolor density plot showing the correlated expression of CD20 Rituximab Biosimilar or Ig Isotype control staining versus CD19 was derived from gated events with the forward and side light-scatter characteristics of intact lymphocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo Software. Show More Multiparameter flow cytometric analysis of Human CD20 Rituximab Biosimilar expression on Human peripheral blood leukocytes. Human whole blood was stained with either BD OptiBuild BV421 IgG1, kappa N297A Human Isotype Control Cat. No. 756231; Left Plot or BD Horizon BV421 Biosimilar Anti-Human CD20 Rituximab297 antibody Cat. No. 570361/570431; Right Plot . The erythrocytes were lysed with BD FACS Lysing Solution Cat. No. 349202 . The bivariate pseudocolor density plot showing the correlated expression of CD20 Rituximab Biosimilar or Ig Isotype control staining versus side light-scatter SSC-A signals was derived from gated events with the forward and side light-scatter characteristics of intact leukocyte populations. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo Software. Show More Two-color flow cytometric analysis of Human CD20 Rituximab Biosimilar expression on Human peripheral blood lymphocytes. Human whole blood was stained with APC Mouse Anti-Human CD19 antibody Cat. No. 555415 and with either BD OptiBuild BV421 IgG1, kappa N297A Human Isotype Control Cat. No. 756231; Left Plot or BD Horizon BV421 Biosimilar Anti-Human CD20 Rituximab297 antibody Cat. No. 570361/570431; Right Plot . The erythrocytes were lysed with BD FACS Lysing Solution Cat. No. 349202 . The bivariate pseudocolor density plot showing the correlated expression of CD20 Rituximab Biosimilar or Ig Isotype control staining versus CD19 was derived from gated events with the forward and side light-scatter characteristics of intact lymphocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo Software. Multiparameter flow cytometric analysis of Human CD20 Rituximab Biosimilar expression on Human peripheral blood leukocytes. Human whole blood was stained with either BD OptiBuild BV421 IgG1, kappa N297A Human Isotype Control Cat. No. 756231; Left Plot or BD Horizon BV421 Biosimilar Anti-Human CD20 Rituximab297 antibody Cat. No. 570361/570431; Right Plot . The erythrocytes were lysed with BD FACS Lysing Solution Cat. No. 349202 . The bivariate pseudocolor density plot showing the correlated expression of CD20 Rituximab Biosimilar or Ig Isotype control staining versus side light-scatter SSC-A signals was derived from gated events with the forward and side light-scatter characteristics of intact leukocyte populations. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo Software.